Connect with us

Technology

Laboratory Automation Systems Market size is set to grow by USD 2.01 billion from 2024-2028, Increasing demand for laboratory automation software services boost the market, Technavio

Published

2 years ago

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global laboratory automation systems market size is estimated to grow by USD 2.01 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 8.68%  during the forecast period. Increasing demand for laboratory automation software services is driving market growth, with a trend towards rising number of FDA-approved manufacturing facilities in developing nations. However, lack of adoption of automated solutions by small-scale and medium-scale laboratories  poses a challenge. Key market players include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Co., Bee Robotics Ltd., Biosero Inc., Cognex Corp., Eppendorf SE, F. Hoffmann La Roche Ltd., Gilson Inc., LabVantage Solutions Inc., LabWare Inc., Olympus Corp., PerkinElmer Inc, QIAGEN NV, SCINOMIX, Siemens AG, SPT Labtech Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Laboratory Automation Systems Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 8.68%

Market growth 2024-2028

USD 2.01 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.26

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Germany, UK, China, and Japan

Key companies profiled

Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Co., Bee Robotics Ltd., Biosero Inc., Cognex Corp., Eppendorf SE, F. Hoffmann La Roche Ltd., Gilson Inc., LabVantage Solutions Inc., LabWare Inc., Olympus Corp., PerkinElmer Inc, QIAGEN NV, SCINOMIX, Siemens AG, SPT Labtech Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

The outsourcing of medical device manufacturing and drug discovery is a significant trend in the healthcare industry, driven by the need for US FDA-approved facilities, skilled labor at reasonable costs, and adherence to World Health Organization-Good Manufacturing Practice (WHO-GMP) standards. India is an attractive destination for healthcare contract research outsourcing due to its large number of US FDA-approved manufacturing plants, a talented workforce, and cost advantages. The implementation of product patents under the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement in 2005 further fueled outsourcing from developed markets. With the increasing demand for high-volume product orders, developing countries are investing in infrastructure and expertise, leading to the growth of the global laboratory automation systems market. The availability of efficient and cost-effective drug discovery in these countries is also contributing to market expansion during the forecast period. 

Laboratory automation systems are trending in the scientific community due to their ability to increase productivity, ensure safe working conditions, and provide reliable results in less time and effort. Integrated systems are becoming the norm, addressing issues like sample contamination and streamlining workflows. Automation dependence is growing, with robots restocking shelves and handling samples, while wireless connectivity enables seamless data transfer. High-throughput compound screening and fragment screening are key applications, with computer modeling and machine learning aiding potential therapeutic candidates’ discovery. FDA clearance is crucial for life-saving medical equipment, while precision medicine development relies on automated instruments for process automation. Sample handling, verifications, and labeling tubes are essential components, ensuring accurate results. Manufacturing machinery benefits from automation, reducing costs and improving efficiency. Immersive experiences and wireless connectivity enhance the user experience, making laboratory automation technology an indispensable tool for clinical laboratories. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

Small- and medium-scale laboratories typically handle a lower volume of samples and focus on specific applications, such as diagnosis and testing of biological samples. Due to limited budgets, staff, and planning, automation is not a priority for these laboratories. Additionally, they often lack the necessary floor space for large-scale automation systems. In contrast, large-scale facilities can afford advanced automated solutions for processes like chemically relevant compound profiling, high-content screening, and large-scale cell culture development. However, small- and medium-scale laboratories are hesitant to invest in these technologically advanced products due to high maintenance and service costs related to laboratory informatics solutions. The lack of knowledge among professionals managing these laboratories regarding the benefits of automation further hinders adoption. These factors limit the growth of the global laboratory automation systems market during the forecast period.The Laboratory Automation Systems market is witnessing significant growth due to the increasing demand for automated solutions in various industries such as healthcare, food safety, and research. However, challenges persist in this market, including physical strain on lab personnel, miniaturization requirements in microbiology and biotechnology, and the need for accurate data analysis in clinical chemistry. To address these challenges, automated systems are being adopted for tasks like liquid handling, data management, and sample preparation. Government legislation, regulatory requirements, and budget constraints are also driving the market for automated systems. The total automation segment, including automated workstations and robotic systems, is experiencing high demand, especially in diagnostics, drug discovery, genomics, and proteomics. Customization services are essential to meet the unique needs of laboratories, whether high volume or specialized in forensics or healthcare applications. The market is expected to continue growing, offering benefits such as reduced repetitiveness, human intervention, time cycle, and improved data quality.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This laboratory automation systems market report extensively covers market segmentation by  

End-user 1.1 Pharmaceutical and biotechnology companies1.2 Clinical and reference laboratories1.3 Academic institutions and research organizations1.4 OthersType 2.1 Equipment2.2 Software2.3 servicesGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Pharmaceutical and biotechnology companies-  Pharmaceutical and biotechnology companies are increasingly utilizing laboratory automation systems for high-content screening (HCS) applications in their drug discovery processes. Automated liquid handling systems are commonly used for screening clinically relevant compounds, isolating those with specific properties, and quantifying and analyzing screening assays. These systems can operate for extended periods with minimal supervision, enabling companies to focus on their core work and reduce time spent on repetitive tasks. Innovations like integrating analytical systems with software programs expedite the process and make it cost-effective. Longer runtimes and larger system sizes are further driving adoption. The emergence of new pharmaceutical and biotech firms focusing on novel drugs and molecular therapies is fueling market growth in this sector during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

Laboratory Automation Systems (LAS) are technological solutions designed to automate various laboratory processes, enhancing productivity, ensuring safe working conditions, and delivering reliable results. LAS encompasses automation of process steps such as sample handling, liquid handling, high throughput analysis, clinical chemistry analysis, and immunoassay analysis. These systems enable advanced data management, reduced human intervention, and total automation in segments like healthcare applications, clinical laboratories, diagnostic laboratories, and research institutions. Automated workstations and robotic systems are integral components of LAS, streamlining sample preparation and data analysis. LAS plays a pivotal role in improving laboratory efficiency, reducing errors, and ensuring consistent and accurate results.

Market Research Overview

Laboratory automation refers to the use of technology to automate various processes in laboratories, including the use of automated instruments for sample handling, verifications, labeling tubes, and data analysis. This technology offers numerous benefits, such as increased productivity, safe working conditions, reliable results, and reduced time and effort. Automated systems are used extensively in clinical laboratories, microbiology, biotechnology, clinical chemistry, and immunoassay analysis, among others. The market for laboratory automation systems is driven by the need for efficient and accurate laboratory processes, regulatory requirements, and government legislation. Automation enables reduction of repetitiveness and human intervention, resulting in enhanced workflow scope, reduced time cycle, and improved data quality. Automated liquid handlers, sample preparation, and data management are key components of laboratory automation systems. Miniaturization and immersive experience are emerging trends, with wireless connectivity and robots restocking shelves adding to the convenience. End users in the healthcare sector, including hospitals and diagnostic laboratories, are major consumers of laboratory automation systems. Budget constraints and emerging countries present opportunities for growth in the market. The diagnostics segment, including drug discovery, genomics solutions, proteomics solutions, and forensic laboratories, is a significant contributor to the market. Automated workstations, off-the-shelf automated workcells, and robotic systems are popular solutions. The total automation segment, with customization services, is gaining popularity due to the increasing complexity of laboratory needs. High volume laboratories, tables and accessories, and healthcare applications are other areas of focus. Laboratory automation systems offer significant benefits, including reduced repetitiveness, increased productivity, and improved data quality. However, challenges such as sample contamination, automation dependence, and FDA clearance must be addressed to ensure the success of these systems. Machine learning, InsilicoMedicine, and precision medicine development are emerging areas of application for laboratory automation systems. The potential therapeutic candidates identified through high-throughput compound screening and fragment screening offer significant opportunities for advancements in healthcare and manufacturing machinery.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userPharmaceutical And Biotechnology CompaniesClinical And Reference LaboratoriesAcademic Institutions And Research OrganizationsOthersTypeEquipmentSoftwareServicesGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/laboratory-automation-systems-market-size-is-set-to-grow-by-usd-2-01-billion-from-2024-2028–increasing-demand-for-laboratory-automation-software-services-boost-the-market-technavio-302210040.html

SOURCE Technavio

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Ontario Superior Court Awards Over $170 Million in Damages to Mutual Fund Investors in Landmark Class Action Decision

Published

4 minutes ago

on

July 18, 2026

By

TORONTO, July 17, 2026 /PRNewswire/ — On July 16, 2026, Justice Markus Koehnen of the Ontario Superior Court of Justice ordered CI Mutual Funds Inc. and AIC Limited to pay Class Members damages and interest in excess of $170 million.

The Market Timing class action, commenced in 2006, alleged that certain mutual fund managers permitted sophisticated offshore hedge fund investors to engage in frequent trading in their funds, that substantially diluted the investment of long-term investors, including retail unitholders, many of whom were retirees.

Rochon Genova has represented the long-term investors since the inception of this case, including before the Supreme Court of Canada, on appeal from an earlier certification motion.  The Supreme Court certified the case in 2013. A subsequent case management order divided the trial into two phases: a trial in respect of liability, and a subsequent trial in respect of damages. The liability trial was held in February, March and June 2022.

On February 13, 2023, Justice Koehnen issued reasons for judgment in respect of the liability trial.  Justice Koehnen found that both CI and AIC breached their duty of care to prevent “market timing” in their funds. The liability decision, indexed as Fischer v. IG Investment, 2023 ONSC 915, is available here.

The damages trial was heard before Justice Koehnen between March 28 and May 16, 2025. Closing submissions were heard on July 30, August 6 and August 7, 2025. In total, Class Counsel spent 41 days in trial on liability (24 days) and damages (17 days). On June 16, 2026, Justice Markus Koehnen of the Superior Court of Justice issued reasons for judgment in respect of the damages trial.

The Court accepted the evidence of the Plaintiffs’ expert, Professor Eric Zitzewitz, and determined that the “Next Day NAV method” of calculating damages was the appropriate methodology to use, as it measures the specific harm that the time zone arbitrage at issue caused, harm referred to as dilution.

Justice Koehnen determined that the “profits method”, the method of calculating damages advocated for by CI’s expert, was not appropriate as it “measures the wrong thing”. The Court determined that on a balance of probabilities, the “prerequisites of using the profits method” had not been met.

Ultimately, with respect to CI, the Court awarded the Plaintiffs $60,480,000 in damages for the harm resulting from CI’s failure to take appropriate steps to prevent market timing by certain Identified Accounts.

The Court also awarded the Plaintiffs damages caused by specific Additional Accounts at CI that were identified by the Plaintiffs’ expert, Professor Zitzewitz, as having engaged in market timing that harmed the unit holders.

With respect to AIC, the Court awarded the Plaintiffs a total of $37,900,659 in damages, which includes damages caused by the Identified Accounts, and Additional Accounts at AIC that were identified by the Plaintiffs’ expert as having engaged in market timing. 

The Court determined the Plaintiffs are also entitled to pre-judgment interest in the amount of 2.8% per annum, to be applied to the damages figures set out above, in addition to costs against both Defendants.

Peter Jervis, a senior partner at Rochon Genova who led the prosecution of this case, stated: “The damages decision sends a clear message that those who fail to safeguard investors from harmful market practices will be held accountable. That this result was achieved after two decades of hard-fought litigation, is a testament to the perseverance of the Representative Plaintiffs and Class Counsel, and to the strength of our judicial system in delivering access to justice in complex cases.”

Joel Rochon, the Managing Partner of Rochon Genova added: “The decision is an important victory not only for the Class Members, but for the integrity of Canadian capital markets. Mutual funds are a cornerstone of the retirement savings of millions of everyday Canadians, and investors are entitled to expect that fund managers will protect them from practices that unfairly dilute the value of their investments.”

The Plaintiffs in this action were represented by Peter Jervis, Joel Rochon, Sarah Fiddes and Jessica Marshall.

For further updates, please visit Rochon Genova’s website here.

View original content:https://www.prnewswire.com/news-releases/ontario-superior-court-awards-over-170-million-in-damages-to-mutual-fund-investors-in-landmark-class-action-decision-302828857.html

SOURCE Rochon Genova

Continue Reading

Technology

Global Commercial Service Robot Shipments Leader KEENON Puts Humanoids to Work at WAIC 2026

Published

4 minutes ago

on

July 18, 2026

By

SHANGHAI, July 18, 2026 /PRNewswire/ — At WAIC 2026, KEENON Robotics is bringing humanoid and specialized service robots onto the same stage—not as competing concepts, but as complementary forms of embodied intelligence working across complete commercial service workflows.

According to IDC, KEENON ranked first worldwide in commercial service robot shipments in 2025, while maintaining its leadership in the global delivery robot market. IDC also sees the industry moving toward a more diversified, multi-form future, where different robot types are deployed according to the needs of specific tasks and environments. KEENON first propose such strategy and WAIC showcase brings that trend to life.

At the booth, the newly introduced hotel laundry scenario demonstrates this approach most clearly. Humanoid robots complete operational tasks such as loading and operating washing machines, retrieving clean laundry, and folding garments, while the DINERBOT T9 supports the wider delivery workflow. Together, they show how humanoid and specialized robots can divide responsibilities and collaborate within a real hotel operation.

Beyond the hotel workflow, KEENON applies the same role-based approach to food and retail service. Drawing on years of customer insight from restaurants and stores, XMAN-R1 takes on front-of-house tasks that combine interaction with object handling—from preparing drinks with NOWWA Coffee to responding to customer requests in dessert and retail settings. Rather than presenting isolated demonstrations, these scenarios show how KEENON is extending proven commercial service workflows into new humanoid capabilities, with every task performed autonomously and without teleoperation.

Through its “general-purpose humanoid + specialized service robot” strategy, KEENON is building a practical path for embodied intelligence: humanoids take on flexible operation and interaction tasks, while specialized robots continue to handle high-frequency delivery and cleaning. At WAIC 2026, KEENON is showing not just more robot forms, but a more complete model for commercial deployment.

With more than 100,000 service robots deployed worldwide across over 70 countries and regions, KEENON has been recognized by global renown brands across various sectors and widely deployed at major brands like Burger King, Buffalo Wild Wings, Hilton, BMW, Lego etc. From 10 to 20+ robots operating in single venues like Hotel Around Pyeongchang to a mixed fleet of 8 robots across 6 types at facilities like Shangri-La’s Trader Hotel, making it world-first intelligent hotel with both humanoid and service robot, KEENON delivers proven multi-robot efficiency.

SOURCE KEENON Robotics Co., Ltd.

Continue Reading

Technology

MDT Introduces TMR1370 Ultra-Low-Power Magnetic Switch IC Enabling More Than Two Years of Standby Operation in CGM Devices

Published

1 hour ago

on

July 18, 2026

By

— Next-Generation TMR Magnetic Switch with Ultra-Low 50nA Maximum Supply Current Expands MDT’s Proven CGM Sensor Portfolio

ZHANGJIAGANG, China, July 18, 2026 /PRNewswire/ — MultiDimension Technology Co., Ltd. (MDT), a leading supplier of magnetic sensors and a pioneer in Tunneling Magnetoresistance (TMR) technology, today introduced the TMR1370 ultra-low-power magnetic switch IC, the newest addition to MDT’s magnetic sensing portfolio for continuous glucose monitoring (CGM) devices. Building on the proven TMR1367, TMR1368, and TMR1369 family, the TMR1370 delivers significantly lower power consumption, enhanced voltage compatibility, and a smaller package to enable next-generation CGM systems with ultra-long standby life.

Optimized for battery-powered CGM devices, the TMR1370 features a maximum supply current of only 50nA, with approximately 30nA typical at a 3V supply. When combined with the magnetic wake-up mechanism widely adopted in CGM devices, the TMR1370 enables more than two years of standby operation, helping extend product shelf life while preserving battery capacity for continuous glucose monitoring after activation.

The TMR1370’s exceptional power efficiency is enabled by MDT’s proprietary TMR technology platform, which combines advanced magnetic sensor design, optimized device architecture, and proprietary wafer process technology to achieve high magnetic sensitivity together with ultra-low power consumption. Complementing MDT’s existing X-axis and Z-axis CGM magnetic switch portfolio, the TMR1370 gives system designers greater flexibility to optimize sensor orientation and mechanical layout for a wide variety of CGM architectures while enabling easy migration from previous-generation devices.

Key Features

Enables more than two years of standby operation in battery-powered CGM devices.50nA maximum supply current, approximately 30nA typical at 3V.Wide 1.8V to 4.0V operating-voltage range.Maximum operating point below 40 Gauss for reliable magnetic wake-up detection.X-axis magnetic sensing optimized for compact CGM designs.Miniature DFN5L package (1.6×1.6×0.5mm) for thinner and lighter wearable medical devices.Complements MDT’s proven X-axis and Z-axis CGM magnetic switch portfolio for flexible system design and simplified migration.

Samples of the TMR1370 are available through DigiKey and MDT’s online store at www.tmr-sensors.com. For volume pricing, delivery information, and technical specifications, contact MDT Global Sales at sales@dowayusa.com.

About MDT
MultiDimension Technology was founded in 2010 in Zhangjiagang, Jiangsu Province, China, with branch offices in Shenzhen, Chengdu, and Ningbo in China, Singapore, Tokyo, Japan, and San Jose, Calif., USA. MDT has developed a unique intellectual property portfolio, and its self-owned state-of-the-art TMR manufacturing facilities that can support volume production of high-performance, low-cost TMR magnetic sensors to satisfy the most demanding application needs. Led by its core management team of elite experts and veterans in magnetic sensor technology and engineering services, MDT is committed to creating added value for its customers and ensuring their success. For more information about MDT please visit http://www.multidimensiontech.com.

Media Contacts
MDT sales department, sales@dowayusa.com, sales@dowaytech.com
Tel: +1-650-275-2318 (US), +86-189-3612-1156 (China)

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mdt-introduces-tmr1370-ultra-low-power-magnetic-switch-ic-enabling-more-than-two-years-of-standby-operation-in-cgm-devices-302828591.html

SOURCE MultiDimension Technology Co., Ltd.

Continue Reading

Trending